Prix Galien

Individualizing SIRT with the Holmium Platform: QuiremScout ® microspheres, QuiremSpheres ® microspheres and Q-Suite™ software Selective internal radiation therapy (SIRT), also referred to as radioembolization (RE), or trans-arterial radio embolization (TARE) is a treatment option for patients with unresectable liver tumors. Liver tumors can originate in the liver - e.g. hepatocellular carcinoma (HCC) and Cholangiocarcinoma (CCA) or be metastases from other origins – e.g. colon or neuroendocrine tumors. The treatment for liver tumors depends on several factors, as the exact location and stage of the cancer, the patients’ liver function and overall performance status. In some patients, treatment with curative intent such as surgery, transplantation or ablation could be utilized. SIRT is an option aimed for patients with unresectable tumors, to limit or pause tumor progression hence trying to improve quality of life and prolong survival. SIRT involves administration of microspheres loaded with a radioactive isotope into the hepatic artery, leading to microembolization of the tumor vascular bed. To avoid any inadvertent distribution of activity to organs other than the liver, which may cause damage to healthy liver parenchyma and may result in serious complications, the safety and efficacy of the procedure is simulated during a workup phase, using a surrogate marker. This step is also needed to predict distribution of microspheres inside the liver. The Holmium Platform is a unique and fully integrated approach to SIRT consisting of three products: QuiremScout ® microspheres, QuiremSpheres ® microspheres, and Q-Suite™ software. QuiremScout ® enhances the work-up procedure of selective internal radiation therapy (SIRT): The actual standard of care for work-up is based on Technetium 99mTc macro aggregated albumin (99mTc-MAA), however particles are different in shape and size compared to the therapeutic microspheres. QuiremScout ® comprises holmium-166 microspheres which are identical to the microspheres used for SIRT treatment with QuiremSpheres ® . QuiremScout ® has proven to be a more accurate predictor of lung shunts1 and intra-hepatic distribution 2 for the therapy in comparison to 99mTc-MAA . The therapeutic effect is based on QuiremSpheres ® emission of beta radiation. In addition, holmium-166 microspheres emit gamma radiation and are paramagnetic; this enables unique imaging capabilities. MEDTECH INNOVATION AWARD Using Q-Suite™, each treatment can then be planned based on each patient specific tumor characteristics which then enables clinicians to take informed patient selection decisions whether SIRT will be safe and effective prior to performing the therapeutic procedure. Q-Suite™ will also allow clinicians to perform quantitative dose verification after QuiremSpheres ® treatment, to ensure the patients lesion(s) have received an effective dose whilst sparing the healthy tissue. Patients can then be followed up and a decision can also be made to retreat if the delivered dose is deemed suboptimal. Q- Suite ™ Quirem Scout ® Software Microspheres Microspheres 38 | PRIX GALIEN NEDERLAND 2020-2021 PRIX GALIEN NEDERLAND 2020-2021